Acadian Asset Management LLC Trims Stock Position in uniQure N.V. $QURE

Acadian Asset Management LLC trimmed its stake in uniQure N.V. (NASDAQ:QURE) by 3.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 250,104 shares of the biotechnology company’s stock after selling 7,717 shares during the period. Acadian Asset Management LLC owned 0.46% of uniQure worth $2,650,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Northern Trust Corp raised its stake in uniQure by 2.1% in the fourth quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company’s stock worth $1,688,000 after buying an additional 1,923 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of uniQure by 6.0% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company’s stock worth $1,253,000 after acquiring an additional 3,996 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of uniQure by 3.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 279,999 shares of the biotechnology company’s stock worth $2,968,000 after acquiring an additional 10,019 shares in the last quarter. Mraz Amerine & Associates Inc. purchased a new position in shares of uniQure in the 1st quarter valued at approximately $106,000. Finally, Two Sigma Advisers LP lifted its stake in shares of uniQure by 1.4% in the 4th quarter. Two Sigma Advisers LP now owns 756,900 shares of the biotechnology company’s stock valued at $13,367,000 after purchasing an additional 10,400 shares during the period. Institutional investors own 78.83% of the company’s stock.

uniQure Stock Performance

QURE stock opened at $14.84 on Tuesday. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98. uniQure N.V. has a 1 year low of $4.45 and a 1 year high of $19.18. The company has a market cap of $814.27 million, a P/E ratio of -3.79 and a beta of 0.13. The stock’s fifty day moving average price is $15.29 and its 200-day moving average price is $14.01.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.20. The firm had revenue of $5.26 million for the quarter, compared to analysts’ expectations of $5.00 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. On average, equities analysts forecast that uniQure N.V. will post -3.75 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on QURE shares. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a report on Saturday, August 2nd. Mizuho upgraded shares of uniQure from a “neutral” rating to an “outperform” rating and set a $30.00 price target for the company in a research note on Thursday, August 14th. HC Wainwright reissued a “buy” rating and set a $70.00 price target on shares of uniQure in a research report on Friday, September 5th. Chardan Capital reissued a “buy” rating and set a $35.00 price objective on shares of uniQure in a research note on Monday, September 8th. Finally, Cantor Fitzgerald set a $47.00 target price on shares of uniQure in a research note on Wednesday, July 30th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, uniQure has a consensus rating of “Buy” and a consensus price target of $37.45.

Insider Activity

In related news, Director Robert Gut sold 3,336 shares of the business’s stock in a transaction on Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $48,205.20. Following the sale, the director owned 56,879 shares in the company, valued at approximately $821,901.55. The trade was a 5.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director David D. Meek sold 2,112 shares of the company’s stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $30,518.40. Following the sale, the director owned 34,190 shares in the company, valued at approximately $494,045.50. This trade represents a 5.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 17,474 shares of company stock worth $251,722. 4.79% of the stock is currently owned by insiders.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.